Zhaoke Ophthalmology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Zhaoke Ophthalmology şirketinin toplam hissedar öz sermayesi CN¥2.0B ve toplam borcu CN¥224.6M olup, bu da borç-öz sermaye oranını 11% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.4B ve CN¥351.8M dir.

Anahtar bilgiler

11.0%

Borç/özkaynak oranı

CN¥224.63m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥1.41b
Eşitlik	CN¥2.03b
Toplam yükümlülükler	CN¥351.80m
Toplam varlıklar	CN¥2.38b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6622 'nin kısa vadeli varlıkları ( CN¥1.8B ) kısa vadeli yükümlülüklerini ( CN¥318.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6622 şirketinin kısa vadeli varlıkları ( CN¥1.8B ) uzun vadeli yükümlülüklerini ( CN¥33.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6622 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 6622 şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6622 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 6622 serbest nakit akışı her yıl % 21.9 1.8 yıl yetecek nakit akışına sahip olacaktır.

Zhaoke Ophthalmology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Zhaoke (Guangzhou) Ophthalmology Limited Announces Completion of Phase III Clinical Trial

First half 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.43 loss in 1H 2023)

Zhaoke Ophthalmology Limited to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Market cap size

Consensus revenue estimates decrease by 73%

Zhaoke Ophthalmology Limited, Annual General Meeting, May 31, 2024

Zhaoke Ophthalmology Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus EPS estimates upgraded to CN¥0.74 loss

Consensus EPS estimates upgraded to CN¥0.74 loss

New minor risk - Share price stability

Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia

Zhaoke Ophthalmology Limited Announces Executive Changes

Zhaoke Ophthalmology Limited Announces Executive Changes

Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China

Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A (CSA) Ophthalmic Gel

Zhaoke Ophthalmology Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2025

Zhaoke Ophthalmology Limited Announces Cyclosporine A (Csa) Ophthalmic Gel Passed the On-Site Regulatory and Clinical Trial Inspections

Less than half of directors are independent

Zhaoke Ophthalmology Limited Announces Patient Enrollments Complete for Zky001 of Phase Ii Clinical Trial for Tprk, Phase Ii Clinical Trial for Pterygium and Iit for Nk

Forecast to breakeven in 2024

Zhaoke Ophthalmology Limited to Report Q2, 2022 Results on Aug 24, 2022

Zhaoke Ophthalmology Limited Announce First Patient Enrollment in Phase II Clinical Trial of ZKY001 for Transepithelial Photorefractive Keratectomy

Zhaoke Ophthalmology Limited Announces Patient Enrollment Complete for Phase III Clinical Trials of NVK002 for Treatment of Myopia Progression

Zhaoke Ophthalmology Limited Announces First Patient Enrolled in TAB014 Phase III Clinical Trial in China

Zhaoke Ophthalmology Limited Announces New Drug Application of Cyclosporine A Ophthalmic Gel Is Accepted for Review by the Center for Drug Evaluation

Zhaoke Ophthalmology Limited Announces Executive Appointments

Zhaoke Ophthalmology Limited Announces First Patient Enrolled for NVK002 Phase III Bridging Clinical Trial (Mini-CHAMP) in China

Less than half of directors are independent

Zhaoke Ophthalmology Limited, Annual General Meeting, May 31, 2022

Zhaoke Ophthalmology Limited Announces Resignation of Tam Lai Fan Gloria as Independent Non-Executive Director and Member of the Audit Committee

Zhaoke Ophthalmology Limited Announces the Last Patient Enrolled for the Phase II Clinical Trial of One of the Company's Core Products, Zky001

Zhaoke Ophthalmology's IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE

Zhaoke Ophthalmology Limited Announces the Pivotal Phase III Clinical Trial of Core Drug Candidates, Cyclosporine A

Zhaoke Ophthalmology Limited Announces Approval by the Hainan Provincial Medical Products Administration for the Import of an Urgently Needed Drug, Ntc010

Zhaoke Ophthalmology Limited Announces IND Application of NVK-002 for Phase III Clinical Trial in China Accepted for Review by the CDE

Zhaoke Ophthalmology Limited Announces Last Patient Completes the Treatment for Phase III Clinical Trial of Cyclosporine A (CSA) Ophthalmic Gel

Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdong Medical Products Administration

Zhaoke Ophthalmology Limited has completed an IPO in the amount of HKD 2.075934 billion.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin